To analyze the link of serotonin with obesity. To discuss the clinical implications with regard to management options and problems. The development of a broader theory of innovative psychopharmacotherapy. The current perspectives on depression and anxiety and the entity of mixed anxiety depression are reviewed. Specialized groups such as addicts, medically ill and geriatric patients, have their own particular problems - relevant aspects are examined in the pharmacologic context.
Special subdivisions lead to a more fruitful approach as to the patient s pharmacologic needs.
Three clinical scenarios relate to patients who fail treatment after receiving selective serotonin re-uptake inhibitor drugs. This paper examines theoretical and practical options using combination serotonin antidepressant therapy and then looks at new single drug approaches as well as links with obesity. A broader theory of management of depressed and obese patients can be developed with the understanding of concepts such as neuromodulation, partial agonism and the serotonin bathtub analogy in depression. The numerous antidepressant compounds are evaluated for side-effect profile with emphasis on serotonin excess symptoms. Serotonin modulates many basic functions at a large number of levels allowing explanations of why its influences are so diverse.